RhumbLine Advisers’s Denali Therapeutics DNLI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
$2.97M Buy
212,503
+22,247
+12% +$311K ﹤0.01% 1669
2025
Q1
$2.59M Sell
190,256
-134
-0.1% -$1.82K ﹤0.01% 1687
2024
Q4
$3.88M Buy
190,390
+497
+0.3% +$10.1K ﹤0.01% 1547
2024
Q3
$5.53M Sell
189,893
-4,966
-3% -$145K 0.01% 1377
2024
Q2
$4.52M Buy
194,859
+22,900
+13% +$532K ﹤0.01% 1454
2024
Q1
$3.53M Buy
171,959
+5,196
+3% +$107K ﹤0.01% 1600
2023
Q4
$3.58M Sell
166,763
-2,361
-1% -$50.7K ﹤0.01% 1606
2023
Q3
$3.49M Buy
169,124
+7,142
+4% +$147K ﹤0.01% 1550
2023
Q2
$4.78M Buy
161,982
+15,840
+11% +$467K 0.01% 1402
2023
Q1
$3.37M Buy
146,142
+3,210
+2% +$74K ﹤0.01% 1546
2022
Q4
$3.98M Buy
142,932
+14,999
+12% +$417K 0.01% 1411
2022
Q3
$3.93M Buy
127,933
+10,458
+9% +$321K 0.01% 1371
2022
Q2
$3.46M Buy
117,475
+20,330
+21% +$598K 0.01% 1465
2022
Q1
$3.13M Buy
97,145
+496
+0.5% +$16K ﹤0.01% 1582
2021
Q4
$4.31M Sell
96,649
-756
-0.8% -$33.7K 0.01% 1438
2021
Q3
$4.91M Buy
97,405
+2,550
+3% +$129K 0.01% 1372
2021
Q2
$7.44M Buy
94,855
+23,280
+33% +$1.83M 0.01% 1189
2021
Q1
$4.09M Sell
71,575
-8,048
-10% -$460K 0.01% 1523
2020
Q4
$6.67M Buy
79,623
+528
+0.7% +$44.2K 0.01% 1187
2020
Q3
$2.83M Sell
79,095
-11,820
-13% -$424K ﹤0.01% 1496
2020
Q2
$2.2M Buy
90,915
+24,985
+38% +$604K ﹤0.01% 1674
2020
Q1
$1.15M Buy
65,930
+2,418
+4% +$42.3K ﹤0.01% 1815
2019
Q4
$1.11M Buy
63,512
+782
+1% +$13.6K ﹤0.01% 2030
2019
Q3
$961K Sell
62,730
-657
-1% -$10.1K ﹤0.01% 2050
2019
Q2
$1.32M Buy
63,387
+3,204
+5% +$66.5K ﹤0.01% 1942
2019
Q1
$1.4M Sell
60,183
-666
-1% -$15.5K ﹤0.01% 1890
2018
Q4
$1.26M Buy
60,849
+22,712
+60% +$469K ﹤0.01% 1900
2018
Q3
$829K Buy
38,137
+21,926
+135% +$477K ﹤0.01% 2083
2018
Q2
$247K Buy
16,211
+2,306
+17% +$35.1K ﹤0.01% 2627
2018
Q1
$274K Buy
+13,905
New +$274K ﹤0.01% 2479